Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
7 hedge funds and large institutions have $469K invested in Amplify Treatments, Testing and Advancements ETF in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$241K |
| 2 |
BSG
Black Swift Group
Boulder,
Colorado
|
+$135K |
| 3 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
+$45.4K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$10.4K |
| 5 |
PIMG
Patriot Investment Management Group
Knoxville,
Tennessee
|
+$5.4K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WS
1
Wedbush Securities
Los Angeles,
California
| $255K | +$241K | +8,940 | New |
|
|
BSG
2
Black Swift Group
Boulder,
Colorado
| $143K | +$135K | +5,000 | New |
|
|
SFS
3
Sowell Financial Services
North Little Rock,
Arkansas
| $48K | +$45.4K | +1,680 | New |
|
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $11K | +$10.4K | +385 | New |
|
|
PIMG
5
Patriot Investment Management Group
Knoxville,
Tennessee
| $5.71K | +$5.4K | +200 | New |
|
|
TWA
6
TCI Wealth Advisors
Tucson,
Arizona
| $4K | +$3.78K | +140 | New |
|
|
GWM
7
Geneos Wealth Management
Englewood,
Colorado
| $2K | +$2.7K | +100 | New |
|
GERM Hedge Fund Activity: Q2 2020 in Review
7 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q2 2020, worth a combined $469K.
Buyers outnumbered sellers: 7 funds opened new GERM positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wedbush Securities, opening a new position worth an estimated $241K.
- 7 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $469K of Amplify Treatments, Testing and Advancements ETF stock for Q2 2020.
- 7 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q2 2020 and 0 closed out, a net change of +7 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q2 2020 was Wedbush Securities, an estimated $241K added.
Based on aggregated 13F filings for Q2 2020.